Molecular biology reports · 2025
Interleukin-17 and interleukin-23 cytokine profiles in palindromic rheumatism: potential therapeutic targets and prognostic biomarkers for disease progression to rheumatoid arthritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Javidi-Aghdam Kamran, Akbarzadeh-Khiavi Mostafa, Ghasembaglou Arezoo, Rahbari Bita, Mahdavi Aida Malek, Jafarpour Mehdi, Safary Azam, Khabbazi Alireza
Аннотация
BACKGROUND: Palindromic rheumatism (PR) is a rare autoimmune disorder characterized by recurrent inflammatory episodes, often progressing to more severe forms of arthritis, such as rheumatoid arthritis (RA). The interleukin (IL)-17/23 axis plays a crucial role in autoimmunity and joint inflammation; however, its involvement in PR remains unclear. This study aimed to investigate mRNA expression and serum levels of IL-17 and IL-23 in PR, RA, and healthy controls (HCs).
METHODS: This cross-sectional study included 20 PR patients, 40 RA patients, and 40 age- and gender-matched HCs. Serum cytokine levels and gene expression were assessed using enzyme-linked immunosorbent assay (ELISA) and real-time polymerase chain reaction (qPCR). Correlations between cytokine levels, joint involvement, and disease activity were analyzed.
RESULTS: Serum and mRNA expression levels of IL-17 and IL-23 were significantly higher in PR and RA patients compared to HCs. Notably, IL-17 and IL-23 levels were significantly higher in PR patients than RA patients, suggesting distinct inflammatory mechanisms. There was a significant positive correlation between IL-17 and IL-23 expression levels in PR and RA groups. However, no significant association was found between cytokine levels with clinical manifestations, autoantibodies and disease activity in PR and RA groups.
CONCLUSION: The research findings provide valuable insights into immune imbalances and increased gene expression and protein levels of IL-17 and IL-23 in PR patients, offering potential therapeutic targets. Targeting these cytokines or their receptors may provide novel therapeutic strategies to prevent PR progression to RA.
CLINICAL TRIAL NUMBER: Not applicable.
METHODS: This cross-sectional study included 20 PR patients, 40 RA patients, and 40 age- and gender-matched HCs. Serum cytokine levels and gene expression were assessed using enzyme-linked immunosorbent assay (ELISA) and real-time polymerase chain reaction (qPCR). Correlations between cytokine levels, joint involvement, and disease activity were analyzed.
RESULTS: Serum and mRNA expression levels of IL-17 and IL-23 were significantly higher in PR and RA patients compared to HCs. Notably, IL-17 and IL-23 levels were significantly higher in PR patients than RA patients, suggesting distinct inflammatory mechanisms. There was a significant positive correlation between IL-17 and IL-23 expression levels in PR and RA groups. However, no significant association was found between cytokine levels with clinical manifestations, autoantibodies and disease activity in PR and RA groups.
CONCLUSION: The research findings provide valuable insights into immune imbalances and increased gene expression and protein levels of IL-17 and IL-23 in PR patients, offering potential therapeutic targets. Targeting these cytokines or their receptors may provide novel therapeutic strategies to prevent PR progression to RA.
CLINICAL TRIAL NUMBER: Not applicable.